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Acute Ischemic Syndromes
State of the Art
Coronary artery disease has a heterogeneous range
of clinical presentations that varies from asymptomatic pa-
tients with multivessel disease to patients with one-vessel
disease with acute myocardial infarction (AMI) and even
sudden death. Other patients have stable angina that has
evolved over many years, even decades, without progres-
sing to unstable angina or myocardial infarction (MI). Even
more serious, one third of the cases of coronary disease has
sudden death as its first and only manifestation.
Despite being the main cause of death in developed
countries, more people live with coronary atherosclerosis
than die of it 1,2. Therefore, the most relevant question is not
why atherosclerosis develops, but why a quiescent athe-
rosclerotic plaque suddenly ruptures and, on top of it,
occlusive or subocclusive coronary thrombosis develops.
To understand this remarkable clinical heterogeneity
is not easy, and only the recent advances in vascular biolo-
gy have allowed the understanding of important aspects of
this complex disease. This text focuses only on one form of
this disease presentation, which is the acute ischemic
syndrome (AIS).
Pathogenesis
The atherosclerotic plaque consists of two parts: the
core (atheroma), which is rich in extracellular lipids, has a soft
consistency, and occupies one third of the total volume of
the plaque, and the peripheral component (sclerosis), which
is formed by fibrous tissue, has a hard consistency, and occu-
pies two thirds of the total volume of the plaque. The relative
proportion of each component varies greatly, and there is no
relation between plaque size and its constitution 3,4.
The possibility of developing AIS does not depend
solely on the number, distribution, and degree of stenosis
caused by the atherosclerotic plaque. More than that, a
complex balance between factors extrinsic to the plaque and
their attributes not revealed by coronary angiography are
currently considered.
Currently, the concept that AIS is usually precipitated
by occlusive or subocclusive thrombosis on top of a com-
plicated atherosclerotic plaque is widely accepted. Accor-
ding to this concept, plaque’s disruption and the conse-
quent exposure of its components to blood precipitates
thrombosis 3,5.
The factors determining rupture and subsequent
thrombosis can be both extrinsic and intrinsic to the plaque.
Extrinsic factors
The extrinsic factors comprise the alterations of the
formed elements and chemical components of the blood in
addition to hemodynamic alterations. Several triggers of
acute ischemic events have been identified 2,6. Half of the
acute ischemic events do not occur at random, being trigge-
red by external factors. AMI occurs most frequently in the
morning 7-9, on Mondays 10,11, during the winter 12,13, and du-
ring emotional 14,15 and physical 16,17 stress. Physiologically,
all these conditions have in common the increase of sympa-
thetic tonus.
Muller et al 2 clearly documented the daily variation in
the incidence of MI, which tends to occur more often in the
first hours of the morning than in any other period of the
day. This observation confirmed that the typical adrenergic
stimulus of waking up promotes platelet alterations and
triggers coronary thrombosis. This evidence was confirmed
by the observation that acetylsalicylic acid attenuated the
morning peak of the occurrence of MI.
Later, Leor et al 18 observed an increase in the incidence
of infarction in Los Angeles in the hours and days following
the Northridge earthquake. Curiously, these authors also
noted a reduction in infarction incidence in the weeks and
months that followed the earthquake. This observation
suggests that the adrenergic stimulus associated with the
natural disaster complicated a number of the atherosclerotic
plaques vulnerable to disruption.
AIS can also be precipitated by hemodynamic chan-
ges that can cause modifications of the physical forces that
operate on the atherosclerotic plaque. Bioengineering
studies have documented a marked difference in physical
stress in distinct regions of the plaque, contributing to its
disruption and subsequent thrombosis. These studies
revealed that the thicker the fibrous cap that covers the lipid
core, the smaller the circumferential stress of the wall. In
addition, the greater the volume of the lipid core, the higher
the circumferential stress, especially at the transition bet-
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ween the plaque and the normal vascular wall. More curious,
and less expected, is the observation that the degree of
stenosis has a small influence on the physical stress of the
plaque 19-25. It was recently demonstrated that the maximum
circumferential stress of the plaques responsible for fatal
MI is three times higher than that of uncomplicated plaques.
Furthermore, the disruption site coincided with the region
of higher circumferential stress.
In addition to the prothrombotic influence of the adre-
nergic stimulus described above, there are also concomitant
hemodynamic changes that probably increase the risk of
plaque disruption. According to Laplace’s law, the circumfe-
rential stress of the wall varies directly with the intraluminal
pressure. Thus, the increase of blood pressure increases
the circumferential stress in the plaque. The increase of
inotropism and chronotropism that accompany the eleva-
tion of the adrenergic tonus also increases the compressive
forces upon the plaque, favoring its disruption. Although
intuitive, there is still lack of evidence of the importance of
the hemodynamic changes in the increase of the risk of
plaque disruption.
Another extrinsic factor to the plaque that influences
its thrombotic potential is the alteration of the formed
elements of the blood. It is currently known that the plasma-
tic concentration of fibrinogen increases the risk of corona-
ry events independent of other factors 26. There is a correla-
tion between the variation in the levels of the plasminogen
activator inhibitor 1 (PAI-1) and acute ischemic events,
particularly MI in young individuals 27,28. Another plasmatic
factor is the increase of Lp(a) that competes with plasmino-
gen and, therefore, inhibits plasmin activation. Because
this is a fibrinolytic enzyme, the final fibrinolytic capacity is
depressed.
This set of extrinsic factors to the plaque influences
the precipitation of AIS because they disrupt the natural
balance between thrombosis and fibrinolysis.
Other plasmatic factors that can affect plaque stability
are the plasmatic levels of cytokines and endotoxins. These
mediators of inflammation and systemic response to virus
and bacteria can precipitate AIS when a severe systemic di-
sease occurs. Interleukin-6, in particular, actuates in the liver,
promoting acute phase protein synthesis. Another  is fibrino-
gen, a plasma component surely related to ischemic events.
Although important, the extrinsic factors do not have
an influence in the precipitation of AIS if there is no vulne-
rable plaque as a substrate.
Intrinsic factors
Contemporary pathological studies have established
that the loss of integrity of the atherosclerotic plaque and
subsequent thrombosis is the mechanism of the majority of
AISs. There are two forms of loss of physical integrity of
the plaque: erosion and disruption.
Erosion consists of a superficial loss of integrity with
exposure of the subendothelial basement membrane. The
exposed collagen activates the platelets and the von Wille-
brand factor promotes their aggregation. Atherosclerotic
plaque erosion is responsible for approximately one third of
fatal coronary thromboses in autopsy studies.
Another form of loss of physical integrity is the dis-
ruption of the fibrous cap and subsequent wide exposure of
its highly thrombogenic lipid core. Tissue factor, a potent
procoagulant, significantly contributes to lipid core throm-
bogenic potential 29,30. Tissue factor activates factor VII
beginning the cascade of events that leads to the activation
of factor X, thrombin, and finally to thrombus formation.
This type of wider disruption is responsible for two thirds of
the fatal coronary thromboses.
The disrupting region of the plaque usually exhibits
inflammatory characteristics, especially the wider form of
disruption through the fibrous cap 31. Inflammation at the
most vulnerable region of the plaque is characterized by
elevated concentrations of macrophages and T lympho-
cytes, being independent from the plaque’s morphology.
Microscopically, the complicated plaques responsible
for fatal ischemic events have the following characteristics 20,32:
1) thin fibrous cap 19,33,34; 2) large lipid core 33,34; 3) abundance
of macrophages 24,31,35; 4) paucity of smooth muscle cell 36-38.
The main factor responsible for the integrity of the fi-
brous cap is the interstitial collagen, particularly types I and
III, which are predominantly synthesized by the smooth
muscle cells. Therefore, any factor that reduces the amount
of collagen in the fibrous cap can endanger its integrity.
The reduction of collagen in the fibrous cap can occur
due to three mechanisms: 1) synthesis reduction; 2) degra-
dation increase; and 3) reduction in the amount of smooth
muscle cells. Synthesis reduction can be mediated by
interferon gamma that is produced by activated T lympho-
cytes due to chronic inflammation 39. Degradation increase
depends on a set of proteolytic enzymes named matrix me-
talloproteinases (MMP). These enzymes, usually present
in minimal amounts, have their synthesis increased by
macrophages, particularly in the form of foam cells 40-42.
Although migration and proliferation of smooth muscle
cells are an important component of the atherosclerotic
plaque formation and growth 43,44, these cells are characte-
ristically scarce in the plaques responsible for fatal ischemic
events. This must weaken the plaque because these cells
are the main source of collagen. The probable mechanism
for the reduction of the number of smooth muscle cells is in-
terferon gamma cytokine synthesized by the activated T
lymphocytes. Interferon gamma inhibits the proliferation of
these cells and also activates their programmed death or
apoptosis 45-47. Three cytokines (interferon gamma, IL-
1beta, and TNF-alpha) were recently observed to activate
the apoptosis via the smooth muscle cell 48.
Theoretically, a less common form of plaque rupture is
called centrifuge, because it occurs inside the plaque to-
wards the arterial lumen. This type of rupture requires that
the intraplaque pressure surpass the intraluminal pressure.
This can be precipitated by hemorrhage originating in the
intraplaque vasa vasorum 49,50. This hypothesis, however,
still awaits confirmation.
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Another factor often considered as a cause of acute
ischemic events is coronary spasm 51,52. Even though the co-
existence of spasm and plaque rupture is a common finding,
the observations suggest that the first is more a conse-
quence than a cause of the second 53,54. In reality, it has been
shown that drug-induced spasm rarely causes MI 55.
Clinical repercussions of plaque rupture
Plaque rupture, most of the time, is a common and
asymptomatic phenomenon. Its clinical repercussion de-
pends on the degree of coronary flow limitation caused by
subsequent thrombosis, which is very variable 3. Autopsy
studies reveal that 9% of “normal” individuals who die of
noncardiac causes have coronary plaque complicated with
rupture. This finding increases to 22% in individuals with
diabetes or hypertension 56. On the other hand, in two other
studies of individuals who died from coronary artery
disease, many coronary plaques complicated by rupture
were found 35,57. The complicated plaques that caused the
death showed intense thrombosis with coronary flow
limitation, and the majority of the other complicated plaques
had discreet or no thrombosis.
Therefore, after plaque rupture, the degree of throm-
bosis determines the clinical repercussion. The three main
factors that determine the intensity of the thrombotic res-
ponse to rupture are: 1) rupture extension and composition
of plaque contents 58-60; 2) the degree of stenosis and irregu-
larity of the plaque surface 61,62; 3) balance between throm-
botic and thrombolytic factors at the moment of rupture 63-67.
In the majority of patients with unstable angina, plaque
erosion or rupture resolves with the vascular reparation pro-
cess that results in an increase of the degree of obstruction.
The type of AIS that a given patient develops after
rupture and subsequent thrombosis is determined by four
factors: 1) vessel occlusion velocity; 2) degree of obstruc-
tion: total or partial; 3) magnitude of collateral circulation to
the distal bed of the occluded artery; and 4) occlusion
stability: long-standing or transitory.
Coronary thrombosis in unstable angina and
AMI: similarities and differences
Today it is well established that AIS consists of a con-
tinuum spectrum ranging from unstable angina to AMI.
These syndromes have several aspects in common, such as
variable degree of plaque rupture, variable degree of subse-
quent thrombosis, ischemia usually determined by primary
reduction of oxygen supply due to long-lasting or transito-
ry coronary occlusion or subocclusion. There are, however,
important differences in pathophysiology, which determine
fundamental differences in clinical features, response to trea-
tment, and prognosis (between unstable angina and AMI).
Clinically, unstable angina has several forms of pre-
sentation resulting in different definitions and classifica-
tions. On the other hand, AMI has a form of presentation
that enables a more specific definition.
Several classifications for unstable angina have been
developed, according to clinical, pathophysiological, and
prognostic criteria 68-70. The classification that has been
most used by clinicians and epidemiologists is the one by
Braunwald 71. This classification encompasses three crite-
ria: 1) severity of pain: recent effort angina (<2 months) or
progressive angina (aggravation of previous stable angina)
(class I), subacute angina at rest, with the last painful
episode more than 48 hours before (class II), acute angina at
rest, with the last painful episode within the last 48 hours
(class III); 2) clinical circumstance of angina occurrence:
secondary (A), primary (B), and postinfarction (C); 3)
presence of any form of treatment at the moment of angina
presentation: none (1), oral treatment (2), maximum pharma-
cological treatment (3). In each of these criteria, there is a
progressive scale of prognosis aggravation. Therefore, the
most benign unstable angina is class IA1; the one with the
worst prognosis is class IIIC3 72. According to data obtained
in the Global Unstable Angina Registry and Treatment Eva-
luation (GUARANTEE Study) 73, which involved almost
three thousand patients, two thirds of the cases are class II
or III (subacute or acute angina at rest) and one third is
class I (recent effort angina or progressive angina).
Myocardial ischemia in AISs, such as ischemia in any
tissue, can result from increase in oxygen demand or reduc-
tion in oxygen supply. The increase of oxygen demand cau-
ses approximately one third of the cases of unstable angina
(Braunwald class I) and rarely AMI. On the other hand, the
reduction of the oxygen supply accounts for two thirds of
unstable angina cases and almost all of the AMI cases.
Class II and III unstable angina and AMI are caused
by atherosclerotic plaque rupture and subsequent subo-
cclusive and occlusive thrombosis, respectively. As above
described, plaque complication occurs in variable degrees
from small erosion and localized fissure to extensive and
deep rupture. There is a clear relation between the degree of
the plaque’s anatomical complication and the clinical
expression of this complication. A great number of the small
erosions and ulcerations of the plaque are clinically silent.
Falk 74 and several other researchers 75 have histologically
and angiographically demonstrated that coronary stenosis
causing unstable angina results from repetitive episodes of
plaque ulceration and healing, which cause a slow increase
of the plaque’s volume. Vascular repair subsequent to ulce-
ration and thrombosis can increase the fibrous content
through thrombus organization and incorporation to the
plaque. This not only limits the extension of the subsequent
complication, but also makes the plaque less vulnerable to
future ruptures, which can be interpreted as a natural me-
chanism of arterial passivation.
In unstable angina, coronary thrombosis is usually su-
bocclusive or transitorily occlusive. This type of thrombus
is typically fragile and can cause periods of occlusion of 10
to 20 minutes 76, frequently with a concomitant and transito-
ry coronary spasm component. Spasm can be caused by re-
lease of vasoactive substances by platelets and endothelial
dysfunction 77.
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In non-Q MI, the degree of plaque injury is more signi-
ficant than in unstable angina, resulting in more persistent
occlusive thrombosis, lasting up to one hour 76. Approxima-
tely one forth of the patients with non-Q infarction have a
persistently occluded coronary artery responsible for the
infarction, but also have the distal bed partially protected
by collateral circulation.
In AMI, plaque rupture is often more extensive and
deeper, with intense collagen, cholesterol crystals, and
tissue factor exposure, and consequent long-lasting occlu-
sive coronary thrombosis. It is important to emphasize that
no relation exists between the degree of stenosis caused by
a plaque and the extension and depth of an eventual ruptu-
re. It was recently observed that 40% of the fatal occlusive
coronary thrombi occurred in plaques complicated only by
erosion 78. This observation led to the consideration that
circulating or systemic (monocytes, infection, hypercholes-
terolemia, etc) hemostatic factors can play a significant role
in these cases. In addition, half of the AMI cases are caused
by atherosclerotic plaques that reduce the luminal diameter
to 50% or less, being therefore considered of little prognos-
tic value in infarction-preceding angiographies 78.
Some cases of sudden death probably involve rapidly
progressive coronary injury, where plaque rupture and the
resulting occlusive thrombosis lead to myocardial ischemia
and fatal ventricular arrhythmia in the absence of collateral
circulation 79.
Thrombosis following plaque rupture is a process that
evolves in stages and begins with exposure of subendo-
thelial components, such as collagen, von Willebrand factor,
fibronectin, and vitronectin. These extracellular matrix
components are recognized by the surface receptors of the
platelets, which then adhere to the plaque and become
activated. The activated platelets release a set of substances
from their alpha granules, causing vasoconstriction, che-
motaxis, mitogenesis, and more platelet activation. The
substances involved in this process are thromboxane A2,
serotonin, fibrinogen, plasminogen-activator inhibitor (PAI-
I), and growth factors. Platelet activation leads to exposure
of a particular surface receptor, glycoprotein IIb/IIIa. This
integrin is the via final common pathway of all platelet
aggregation agonists, and is also known as fibrinogen recep-
tor 80. Aggregation consists of ligation and connection bet-
ween multiple platelets, occurring through fibrinogen bridges
and accelerating thrombin production. In a reciprocal manner,
the generated thrombin is a potent platelet activator that
stabilizes the thrombus, converting fibrinogen into fibrin.
Sherman et al 81 performed angioscopy on 10 patients
with unstable angina.  Angioscopy revealed exuberant struc-
tural abnormalities in the intima of all patients and thrombus
in seven. Patients with progressive angina had plaques with
complex morphology, and those with angina at rest had
nonocclusive thrombus at the moment of the examination.
As coronary thrombosis is responsible for the great
majority of AISs, some researchers tried to identify plasma-
tic markers of thrombosis and platelet aggregation. Fibrino-
peptide A (FPA) is a polypeptide resulting from the trans-
formation of fibrinogen into fibrin mediated by thrombin.
Patients with unstable angina have serum levels of FPA
much higher than patients with stable angina or with chest
pain of noncardiac origin 82. Other authors reproduced these
findings 83,84. Zalewski et al 85 observed elevated levels of
PAI-I, a marker of platelet aggregation, in patients with
unstable angina. Fitzgerald et al 86 verified that 84% of the
episodes of angina at rest were associated with transitory
elevation of thromboxane, suggesting a temporal relation
between platelet activation and a clinical event. Some con-
troversial data in relation to the presence of plasmatic markers
of active thrombosis can be attributed to the heterogeneity of
the patients with unstable angina studied, to the small
amount of thrombus present in some lesions, and to the
transitory presence of the hemostatic factors in circulation 87.
Epidemiology
AISs are the main cause of adult hospitalization in the
United States. In recent years, the incidence of unstable an-
gina has rapidly increased. With better population informa-
tion, longer survival of patients with AMI, population
aging, and better diagnostic efficiency of chest pain of is-
chemic origin, this incidence should continue to increase. In
many coronary care units, unstable angina surpassed AMI
as the main cause of hospitalization in the last decade 88. In
the US, it is estimated that there are 700 000 hospitalizations
annually due to unstable angina and another 700 000 cases
occur in which the diagnosis either is not made or the patien-
ts are treated on an outpatient basis. It is also estimated that
1.5 million cases of AMI occur and that 20% of patients die
prior to medical care 89. Only 30% to 50% of the patients
hospitalized with a suspicion of AMI have the diagnosis
confirmed 78. Therefore, AIS occurs in epidemic proportions.
Clinical, electrocardiographic and enzymatic
features
Chest pain of unstable angina differs from that of sta-
ble angina mainly because it is more unpredictable, intense
and longer lasting. On the other hand, patients with AMI
present with a typically more intense and longer-lasting
chest pain, accompanied by other clinical signals, such as
dyspnea, nausea, vomiting, and intense sweating. Howe-
ver, the presentation can be similar to that of an episode of
unstable angina. In this case, diagnostic differentiation in
the emergency room is provided by electrocardiogram
(ECG), which is characterized by ST segment elevation.
ST segment  elevation  in the presence of precordial
pain is generally interpreted as transmural infarction caused
by occlusive thrombosis of the coronary artery responsible
for the infarction. On the other hand, ST segment depression
indicates subendocardial ischemia of unstable angina or of
non-Q infarction caused by coronary subocclusive or
transitory and recurrent occlusive thrombosis.
Therefore, no matter what the clinical presentation of
the AIS at the emergency room is, the main information for
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the immediate diagnostic definition in order to guide the
treatment of recanalization is the presence or absence of ST
segment elevation. Less common is the clinical presentation
of AMI and ECG with left bundle branch block, a situation
that has the same interpretation and treatment as that of
patients with ST segment elevation 78.
Among the patients in the emergency room with chest
pain that causes suspicion of coronary artery disease, there
are two aspects of evaluation that are complementary and
equally important: evaluation of the risk of coronary artery
disease and evaluation of the risk of unfavorable clinical
evolution 90. At the end of this evaluation, the diagnosis can
be one of the following: chest pain of noncardiac origin,
stable angina, unstable angina, or AMI.
A diagnostic and prognostic resource of growing use
in the evaluation of patients with unstable angina is the
dosage of the enzyme troponin T and I. These enzymes are
usually absent or present in very small amounts in the plas-
ma. In the presence of chest pain that causes a suspicion of
unstable angina, the abnormal presence of these enzymes
is an important marker for the occurrence of future clinical
events such as infarction and death 91-93.
Coronary angiography
Coronary angiography has contributed in a significant
way to the understanding of AISs through the historical stu-
dies of DeWood 94 and Ambrose 95. Serial angiographies of
patients with unstable angina have shown one, two or three
vessel  disease in 15%, 35%, and 50%, respectively 96-98. Co-
ronary artery disease extension in patients evaluated in the-
se studies is greater than that observed in patients with sta-
ble angina and MI. The TIMI IIIA study 99, which evaluated
the effect of thrombolysis in unstable angina showed one,
two or three vessel disease in 35%, 39%, and 26%, respecti-
vely, which is similar to the findings in patients with stable
angina. When all the patients with unstable angina who
underwent coronary angiography are considered, a signifi-
cant stenosis  of the left main coronary artery is observed in
5% to 10% of the patients, but 10% to 15% exhibit normal
coronary arteries or nonsignificant stenoses.
The incidence of thrombus revealed by coronary
angiography in unstable angina varies from <10% in
patients with pain in the 30 days preceding the catheteri-
zation 100 until >50%, in those with pain at rest in the last 24
hours 101-103.
An important aspect that favors the indication of early
coronary angiography in patients with unstable angina is
that almost half of these patients have coronary multivessel
disease or stenosis of the left main coronary artery, benefi-
ting, therefore, from early surgical revascularization.
Coronary angiography in the first hours of the evolu-
tion of infarction was first described by DeWood et al 94,
who verified that occlusive coronary thrombosis was pre-
sent in 85% of the cases with transmural infarction. With
time, spontaneous recanalization occurs in up to half of the
patients. These findings had a great impact in the modern
treatment of AMI, concentrating all efforts in the early res-
toration of the coronary flow with thrombolysis or coronary
angioplasty.
Treatment
The pathophysiological substrates of unstable angi-
na and AMI have similarities that also lead to a strategy of
pharmacological treatment with similarities. The pathophy-
siological similarities of plaque rupture, subsequent throm-
bosis, and ischemia of supply due to coronary occlusion or
subocclusion demand control of the thrombotic process
and reestablishment of the balance between oxygen supply
and consumption. These objectives are met with antithrom-
botic and antiischemic drugs. The basic pathophysiologi-
cal difference between unstable angina and AMI, however,
is that in unstable angina, the coronary flow is only transito-
rily interrupted, but in AMI there is a lasting coronary occlu-
sion due to the thrombus. Therefore, in AMI the primary
and immediate treatment goal is to reestablish the flow with
reperfusion therapy. On the other hand, in unstable angina,
the treatment aims to avoid the progression of the sub-
occlusive or transitorily occlusive coronary thrombosis to
stable and long-lasting coronary thrombosis. This strategy
is mainly based on the data analysis of the Fibrinolytic
Therapy Trialists’ Collaborative Group104. This group of
investigators combined the results of nine large scale
studies of thrombolysis, including 58.6 thousand patients,
of whom 32,346 with AIS ST segment elevation and 4,237
with depression of the ST segment. The group with ST
segment elevation treated with thrombolysis had a 19%
higher survival rate than that treated with placebo. The
group with ST segment depression had a 10% smaller
survival rate.
As this is a fundamental and urgent difference, at the
emergency room AIS should be seen as composed of two
distinct groups based on the ECG: AIS with and without ST
segment elevation. The first group should be consistently
considered for chemical or mechanical recanalization, and
the second group should be considered only for anti-
platelet, antithrombin, and antiischemic therapy.
Unstable angina
Immediate clinical treatment must be initiated in any
patient suspected of unstable angina. The treatment objec-
tives are the control of myocardial ischemia symptoms, and
prevention of evolution to MI and death.
The antiischemic treatment consists of reduction of
physical activity, BP control, and administration of antian-
ginal drugs.
Patients with progressing or recent angina (Braunwald
class I) can be initially treated on an outpatient care basis.
The majority of these cases have a good response and the
patients become asymptomatic or olygosymptomatic with
acetylsalicylic acid, beta-blocker and nitrates by oral or
topical via. If clinical risk assessment is favorable, these
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patients remain this way; if it is unfavorable, they should be
referred for catheterization, followed or not by percuta-
neous or surgical revascularization, depending on the ana-
tomy and extension of the coronary artery disease.
Patients with angina at rest and last painful episode
more than 48 hours before (Braunwald class II) should also
initiate outpatient care treatment, except if considered of
intermediate or high risk for MI or death. In this case, they
must be hospitalized, begin oral treatment with acetylsalicy-
lic acid, heparin, beta-blocker and nitrate, and be carefully
observed for 24 to 48 hours for recurrence of symptomatic
myocardial ischemia and dynamic electrocardiographic
abnormalities.
Patients with angina at rest and painful episodes
within the last 48 hours (Braunwald class III) should be
admitted to the coronary unit, begin treatment with acetyl-
salicylic acid, heparin and nitroglycerin intravenously, and
beta-blocker, intravenously or orally. Patients who evolve
with recurrent angina, despite the treatment, should
undergo urgent catheterization aiming to define the
coronary anatomy and, if indicated, proceed to percuta-
neous or surgical revascularization.
These recommendations were published in 1994 105
and have usually been questioned or even ignored becau-
se of the recent and dramatic pharmacological advances
(platelet glycoprotein IIbIIIa inhibitors, low-molecular-
weight heparin) and improvement of the results of coronary
angioplasty due to the widespread use of stents. These
advances have led to a more aggressive initial strategy with
early catheterization followed by angioplasty and early
hospital discharge, frequently before 48 hours. Although
attractive and apparently more economical because this
strategy shortens hospitalization, one should wait for
evidence coming from large-scale randomized multicenter
clinical trials before universally recommending it.
Nitrate administration continues to be routine both for
treatment and for prevention of anginal crises. Nitrates can
be administrated topically, by oral or sublingual via, or
intravenously. Through the relaxation of the endothelium-
independent smooth muscle cell, nitrates reduce the ve-
nous return and the BP. These two effects decrease the wall
stress and, therefore, myocardial oxygen demand. Clinically
less important is the coronary vasodilating effect, particularly
upon spasm-aggravated stenosis. Intravenous nitroglycerin
is indicated for high-risk patients or those with recurrent angi-
na at rest. In addition to angina control, nitrates help to con-
trol BP and ventricular dysfunction. As tolerance to hemody-
namic effects develops quickly, an interruption is recommen-
ded after 24 to 48 hours of use 106. In regard to hemostasis,
nitroglycerin was observed to have a transitory platelet-
antiaggregating effect on the one hand, but it can  also
induce resistance to the anticoagulant effect of heparin.
Beta-blockers are widely used in unstable angina be-
cause they increase the threshold for angina occurrence, pre-
vent recurrent ischemia and death following MI107. They are
specifically effective when there is evidence of sympathetic to-
nus increase characterized by tachycardia and hypertension.
Calcium antagonists are effective in the prevention of
recurrent ischemia, particularly those having a negative ch-
ronotropic effect. Nifedipine, however, should only be used
in association with a beta-blocker, because, isolated, it in-
creases the incidence of clinical events, as demonstrated in
the HINT (Holland Interuniversity Nifedipine/Metoprolol
Trial) 108. Antithrombotic treatment in unstable angina con-
sists of administration of antiplatelet and antithrombotic
agents, aiming to control plaque thrombosis. As coronary
flow is usually preserved, there is no indication of recanali-
zation. In fact, the thrombolytic agent is contraindicated be-
cause it increases platelet activation and aggregation lea-
ding, therefore, to more thrombosis and worse clinical
outcome  104,109.
The standard antiplatelet agent in AIS is acetylsalicy-
lic acid. Its efficacy has been consistently proved. Acetyl-
salicylic acid reduces the risk of fatal and nonfatal MI in
71% in the acute phase 110,111, in 60% in three months 111,112,
and in 52% in two years 113. The beneficial mechanism of
acetylsalicylic acid is the irreversible inhibition of cyclooxy-
genase, blocking the formation of thromboxane A2 and
platelet aggregation. In order to achieve the cyclooxyge-
nase blockade more rapidly, an initial dose of 160 to 325mg is
recommended. The maintenance dose can vary from 80 to
160mg daily. The dose of 80mg daily is as effective as higher
doses and causes fewer collateral effects. Another antipla-
telet agent used when acetylsalicylic acid is contraindicated
is ticlopidine, which inhibits platelet aggregation mediated
by ADP and inhibits platelet glycoprotein IIbIIIa activation.
Ticlopidine at a dose of 250 mg twice a day reduced in 46%
the risk of fatal and nonfatal MI in six months, when compa-
red to placebo 114. The benefit, however, only became appa-
rent 10 days after the beginning of treatment, which suppor-
ts the already known late onset of activity of this drug.
The development of a new group of antiplatelet agen-
ts, the platelet glycoprotein IIbIIIa inhibitors, has changed
the treatment scenario and perspective of AISs, focusing
the strategy more on the control of the thrombus white (pla-
telet) component 115. The first compound of this group to be
widely tested in randomized multicenter trials was abcixi-
mab, which is a monoclonal antibody against the platelet
glycoprotein IIbIIIa, the final common pathway of platelet
aggregation. Other molecules of parenteral use are eptifi-
batide or integrilin, a peptide, and tirofiban and lamifiban, non-
peptide compounds. Abciximab was tested with huge suc-
cess, as an adjunct of coronary angioplasty, aiming to reduce
its complications, such as acute occlusion, AMI and urgent
reintervention 116,117. A particular study, CAPTURE 118, tes-
ted abciximab in a population with refractory unstable angi-
na, whose vessels responsible for the clinical event were
adequate to percutaneous revascularization. The drug was
administered for 18 to 26 hours prior to angioplasty, follo-
wed by infusion during one hour after the procedure. There
was reduction of the combined objectives (death, non-fatal
infarction, or emergency revascularization) from 15.9% to
11.3% (p=0.012) at the 30th day and no benefit at the sixth
month.
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Tirofiban, used in association with acetylsalicylic acid
and heparin, was recently tested in the treatment of unsta-
ble angina and non-Q MI. It proved efficient in reducing
death and incidence of nonfatal MI in 48 hours from 2.6% to
0.9% (reduction of 66%), and in 30 days from 11.9% to 8.7%
(reduction of 30%), when compared to the combined use of
only acetylsalicylic acid and heparin 119. Eptifibatide, used in
association with acetylsalicylic acid and heparin, was also
tested in unstable angina and also proved efficient in redu-
cing nonfatal MI and death from 15.7% to 14.2% (reduction
of 9%) 120. In this study, refractory ischemia was not consi-
dered in the combined objective, which might explain the
smaller reduction of events of 9%, instead of 30% of PRISM-
PLUS 119. In both studies, the benefit was more evident in the
group of patients that later underwent coronary angioplas-
ty, which comprised one third of the cases. In view of these
favorable results, tirofiban and eptifibatide were recently
approved for clinical use. However, in patients surviving an
episode of unstable angina or MI, local activation of the he-
mostatic system lasts for months, causing recurrence of
acute ischemic events. Two trials with platelet glycoprotein
IIbIIIa inhibitors, RESTORE 121 and CAPTURE 118, and one
with thrombin direct inhibitor, GUSTO IIb 122, consistently
showed early benefit. This benefit, however, was variable
and declined considerably over time, coinciding with the
interruption of the administration of the drug. Therefore,
more than one dozen oral platelet glycoprotein IIbIIIa
inhibitors that might be active for a long period are being
exhaustively investigated.
Heparin is recommended for the treatment of unstable
angina based on innumerous randomized studies of mode-
rate size that are strengthened by metaanalysis 123,124. Hepa-
rin is usually intravenously administered in bolus of 5 thou-
sand units, followed by continuous infusion in the neces-
sary dose to keep the activated partial thromboplastin time
two times the basal value. Due to low bioavailability and
necessity of monitoring the anticoagulation of unfractio-
ned heparin, the efficiency of low-molecular-weight hepa-
rins has been tested. The FRISC Study 125 showed therapeu-
tical equivalence between dalteparin and unfractioned he-
parin. The ESSENCE Study 126 showed the superiority of
enoxiparin, which reduced the incidence of nonfatal MI,
death and recurrent angina from 23.3% to 19.8% in 30 days,
an absolute reduction of 3.5% and relative reduction of 15%
(p=0.019). In these two studies, low-molecular-weight
heparin was administered for a few days and new studies are
assessing the possibility of extending the benefit, maintai-
ning the administration for several weeks after hospital
discharge. The advantages of low-molecular-weight he-
parins are its subcutaneous administration and predicting
degree of anticoagulation, which eliminates the need for
monitoring.
Another antithrombotic drug still under research is
hirudin, a direct thrombin inhibitor. A preliminary study with
high doses was prematurely interrupted due to the occur-
rence of hemorrhagic complications 127. A low-dose study
showed benefits in the first days, but these benefits signifi-
cantly decreased in the following 30 days 122. A great study
testing a moderate dose of hirudin is being carried out
based on the favorable results of a pilot study 128.
Considering the placebo group of several recent mega
trials on unstable angina, the prognosis of this syndrome
with conservative treatment with acetylsalicylic acid, hepa-
rin, nitrate, beta-blockers and calcium antagonists is poor,
evolving to death or mainly nonfatal MI in 11% of the cases.
Aiming to improve this prognosis, two randomized studies
compared the conservative clinical treatment with an invasi-
ve initial strategy of myocardial revascularization: the
National Cooperative Study and the Veterans Administra-
tion Cooperative Study 96,129.  Both studies reported that
survival is similar with the two strategies. In the first study,
the one-year survival was 92% and 93% in the surgical and
clinical groups, respectively. There was, however, conside-
rable transfer from the clinical to the surgical group, in these
two studies, and this index was 19% in one year and 34% in
two years. In the Veterans Administration Cooperative Stu-
dy, the advantage of surgical compared to clinical treatment
in two groups of patients was particularly significant. The
five-year survival of patients with multivessel disease was
89% for the group that underwent surgery and 75% for the
group clinically treated 96. Among patients with ventricular
dysfunction and ejection fraction between 30% and 49%,
the survival for the surgical group was 86% compared to
73% for the clinical one.
With the development and wide spread utilization of
coronary angioplasty, the clinical trials were reoriented to
compare the clinical treatment and the invasive treatment
with angioplasty or surgery, depending on coronary anato-
my. On the other hand, the Veteran Affairs non-Q Wave
Infarction Strategies in Hospital Study (VANQWISH) 130
reported a better hospital and one year clinical outcome with
the conservative strategy. The incidence of death and
nonfatal MI during the hospital phase was 3% and 8%,
respectively, in one year, and 18.5% and 24% with clinical
and early invasive (surgery or angioplasty) treatment,
respectively. It is important to stress that the revasculariza-
tion index in 18 months was 44% in the randomized group
for the early aggressive strategy and 33% (p=NS) in the
randomized group for the initial conservative strategy. The-
refore, this data analysis suggests that clinical and invasive
(angioplasty or surgery) treatments are more additive or
complementary than competitive therapeutical options.
When the revascularization option is required, the choice
between angioplasty or surgery is guided by coronary di-
sease extension, morphological aspects of the lesions, esti-
mated risk and awaited benefit of each procedure, and, not
rarely, by the patient’s preference, when both options are
equivalent and this option is offered to the patient by the
assistant physician. In fact, the comparison between angio-
plasty and surgery in patients with multivessel disease has
shown a similar survival, except for the patients with left
main coronary arterial disease and diabetic patients with
multivessel disease 131,132. The majority of patients with uns-
table angina are well-controlled with clinical treatment,
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without recurrence of the myocardial ischemia and have a
favorable prognosis. These patients may not need routine
catheterization and can be properly stratified with noninva-
sive tests of ischemia. A negative exercise test after stabili-
zation of eliminates the possibility of demand myocardial
ischemia related to severe stenosis and is associated with a
low incidence of clinical events in the late follow-up. Pa-
tients with positive exercise (or any other imaging ischemic
test) test are indicative of severe stenosis and should be
referred for invasive stratification with catheterization.
Patients with angina after MI or those who do not stabilize
with clinical treatment are considered high-risk for MI
recurrence or death, and should also undergo catheteriza-
tion aiming to identify a critical coronary stenosis that can
benefit from percutaneous revascularization or surgery.
Recurrence of ischemia in unstable angina in the presence of
clinical treatment indicates lack of disease control, presence
of critical coronary stenosis, or multivessel disease. Intra-
aortic balloon is often indicated to stabilize the more unsta-
ble patients, as a bridging procedure for the more definitive
treatment of the disease 133.
Acute myocardial infarction
Three contributions had a huge impact on the modern
treatment of AMI: first, DeWood et al 94 performed coronary
angiography in patients with AMI and verified that 85% of
the cases had evidence of occlusive coronary thrombosis
in the first hours of onset; second, Rentrop et al 134 demons-
trated acute reperfusion with intracoronary infusion of
streptokinase; third, Reimer et al 135 demonstrated that, in
dogs, coronary occlusion causes a wave of necrosis that
progresses from the endocardium to the epicardium, in a few
hours, and that flow restoration in the first three hours pre-
serves part of the myocardium at risk. These anatomical and
pathophysiological observations guide all established or
under investigation treatment strategies.
Thrombolysis
More than 200 000 patients were studied in randomized
clinical trials in order to test the efficiency of the thromboly-
tic treatment. Around 65 000 were randomized to compare
thrombolysis with placebo or control treatment, and the rest
was randomized to compare different thrombolytic drugs
and regimens. Hospital mortality of AMI was reduced from
around 15% to 8% with thrombolytic treatment 136,137. Despi-
te this brilliant clinical result, the hypothesis of the open ar-
tery in the AMI had often been questioned. Initial studies on
early coronary patency revealed that t-PA (tissue plasmino-
gen activator) was more efficient than streptokinase 138,139.
However, there was no difference in the mortality indices
between these two thrombolytic agents in large-scale rando-
mized studies, such as GISSI II 140 and ISIS III 141. Then, the
hypothesis that t-PA dose and administration regimen may
have been inadequate in these studies appeared, leading to
the speculation that t-PA superiority may have been mas-
ked. These considerations stimulated the design of GUSTO
I (Global Utilization Strategies to Open Occluded Coronary
Arteries) 142. This clinical trial was enriched with an angio-
graphic substudy investigating the relation between early
coronary patency and clinical outcome 143. In GUSTO I,
41,021 patients were randomized for four different thrombo-
lytic strategies: streptokinase plus intravenous or subcuta-
neous heparin, accelerated t-PA plus intravenous heparin,
and streptokinase plus t-PA plus intravenous heparin. The
regimen presenting the highest reperfusion index at 90
minutes was t-PA plus intravenous heparin. This was the
regimen with the smallest mortality rate (6.3 versus 7.3 for
streptokinase plus intravenous heparin, p=0.001). Mortality
reduction was already evident after 24 hours. Normal coro-
nary flow in angiography (TIMI III) at 90 minutes occurred
in 54% with t-PA, versus 31% with streptokinase (p<0.001).
However, there was no difference at 180 minutes (43%
versus 38%, p=NS), suggesting that the difference between
the two thrombolytic agents lies in the precocity of recana-
lization and not in the recanalization rate. These angio-
graphic observations emphasized the importance of the
precocity of coronary patency caused by thrombolysis.
The difference in 30-day mortality can be accurately
anticipated (r2=0.92), based on the difference of the TIMI III
flow index, at 90 minutes 144. The coronary artery patency
related to the infarction was also associated with a higher
late survival. Among the 12,864 patients of GUSTO I who
underwent angiography, the mortality at one year was
smaller when the artery was found patent than when it was
closed: 3.3% versus 8.5% in the clinically treated patients,
2.5% versus 8.5% in those who underwent angioplasty, and
4.2% versus 9.6% in those who underwent myocardial
revascularization 145. Early and thorough reperfusion not
only reduces 30-day and one-year mortality, but it also
results in decreased cardiac morbidity 146, with a smaller
incidence of heart failure, atrial fibrillation, atrioventricular
and intraventricular conducting disorders, and ventricular
arrhythmia.
To confirm the open artery hypothesis, it was obser-
ved that reocclusion eliminates the benefit of the initially
successful thrombolysis 147. In addition, independent from
the thrombolytic regimen used, the 30-day mortality of the
patients without recanalization or with only partial recanali-
zation was 8.9% and of the patients with thorough recana-
lization was 4.0%.
GUSTO I is a landmark study in the modern treatment
of AMI because it demonstrated that reperfusion obtained
with thrombolysis preserves myocardium and lives, and
that this benefit depends primarily on its capacity for early,
thorough and maintained reperfusion.
The choice between streptokinase and t-PA, the two
most commercially available thrombolytic agents, should
involve consideration of the clinical benefits desired and the
cost:effectiveness ratio. These considerations have led to
the proposition of an individualized strategy determined by
the initial risk stratification 148. The high risk markers for
death are: age ³ 65 years, female gender, previous ventricu-
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lar dysfunction, anterior wall infarction, complete left
bundle branch block, marked ST segment elevation, diabe-
tes, heart rate ³ 100bpm, and systolic BP (SBP) <100mmHg at
the moment of hospital admission. In patients with pain for
less than 4 hours, the reperfusion speed is crucial, recom-
mending the accelerated t-PA, except in patients with low
risk of death (young people with inferior infarction) and high
risk of cerebral hemorrhage (BP ³ 170/110mmHg). In these
patients, t-PA and streptokinase are equivalent options,
except for the higher cost of t-PA. For patients with pain
between 4 and 12 hours, low risk of death, but high risk of
cerebral hemorrhage (age >65 years with inferior infarction,
and SBP >100mmHg), streptokinase must be the thromboly-
tic agent of choice.
Ohman et al 149 demonstrated that early reocclusion
determines deterioration of the ventricular function and
doubles the rate of mortality. The incidence of reocclusion
varies from 4.9% to 25%, depending on the thrombolytic
agent and the adjunct therapy 143,150. Reocclusion until one
year after reperfusion can occur in 25-30% of the early
recanalized arteries 146,151. As late patency of the infarction-
related artery is an independent prognostic factor, even
silent late reocclusion can impair the long-term clinical
outcome 144,145. The observation that reduction in mortality
often surpasses the impact obtained in the degree of ventri-
cular dysfunction stimulated the hypothesis that even late
reperfusion can cause clinical benefits through mechanisms
different from those of myocardial preservation 152-154.
These mechanisms can be: flow provision for collateral
circulation 155,156, electrical stability 157,158, reduction of wall
stress and aneurysm formation, attenuation of ventricular
remodeling and dilation 159,160. At least two studies confir-
med that coronary arterial patency is an important predictor
of late survival independent from ventricular function 161,162.
In order to accelerate reperfusion, reduce the resistance to
thrombolysis and prevent reocclusion, several new antith-
rombotic agents, such as direct antithrombinic agents, low-
molecular-weight heparins and antiplatelet agents, are cur-
rently being tested in addition to new thrombolytic agents.
New thrombolytic agents, specifically the plasmino-
gen activators, have been developed and have the follo-
wing properties: longer plasmatic half-life, which allows
bolus administration, higher specificity for fibrin, and
higher resistance to the natural inhibitors of the thromboly-
tic agents, such as PAI-I. The following agents are in diffe-
rent phases of commercial availability or clinical investiga-
tion and have been compared in large-scale randomized stu-
dies with accelerated t-PA, the thrombolytic regimen con-
sidered the gold standard, or with streptokinase: reteplase or
r-PA (INJECT and GUSTO III), lanoteplase or n-PA (InTIME-
2), TNK-tPA (ASSENT-2), saruplase (COMPASS), staphy-
lokinase and an alpha1-plasminogen activator derived from
the saliva of the snake Desmodus rotundus. GUSTO III
demonstrated equivalence between t-PA and r-PA at the
endpoints of death and disabling stroke. The final results of
the studies InTIME-2 and ASSENT-2 are expected during
the first semester of 1999.
All the studies search for the ideal thrombolytic agent,
which should present the following properties: quick reca-
nalization (15-30 minutes), recanalization index close to
100%, quick administration in a single bolus, low index of
cerebral and systemic hemorrhagic complications, specifi-
city for fresh thrombus, low index of reocclusion, sustained
late patency, and reasonable cost 163.
The best available treatment for AMI is the early and
immediate administration of the thrombolytic agent to all
patients without contraindication, who seek the emergency
room within 12 hours of symptom onset and have ST
segment elevation or complete left bundle branch block,
unless mechanical recanalization with coronary angioplasty
is being considered to be safely initiated within 90 minutes
of hospital arrival 163.
Coronary angioplasty
Coronary angioplasty can be used after thrombolysis
failure or after successful thrombolysis to treat severe resi-
dual stenosis despite normal flow at rest. Angioplasty after
unsuccessful thrombolysis, also known as rescue coronary
angioplasty, was assessed in several small observational
studies 164. Even though the success index of the procedure
in restoring flow was 80%, the reocclusion index was 18%
and mortality 10.6%. Considering these results, the RES-
CUE Study 165 was carried out. It randomized patients with
anterior infarction treated with thrombolysis, without evi-
dence of recanalization, for clinical conservative treatment
and to rescue angioplasty. This study showed reduction of
the composite endpoint of death and heart failure, in the
group treated with angioplasty (16.4% versus 6.5%, p=0.05).
This difference was not statistically significant in view of
the low statistical power of the sample in detecting a diffe-
rence that could be clinically significant. Therefore, despite
lack of evidence based on a large-scale randomized clinical
trial, rescue angioplasty has been the standard treatment
when thrombolysis fails and angioplasty is available.
The verification that the reduced mortality obtained
through thrombolysis is primarily related to its capacity for
early and thorough recanalization, and the evidence that
this occurs in more than half the patients treated with throm-
bolysis added to the fact that half of the patients are not
eligible for thrombolysis, stimulated the investigation of
mechanical recanalization through coronary angioplasty, an
option denominated direct or primary angioplasty in AMI.
Several small observational series verified an impor-
tant reduction in mortality with primary angioplasty, leading
to three randomized studies conducted and published
simultaneously 166-168. These studies, which randomized 804
patients, compared different thrombolytic regimens with
primary angioplasty in AMI and showed that mechanical re-
canalization offers a significant reduction in mortality (2.5%
versus 6.4%, p<0.008), in infarction recurrence (2.0% versus
7.9%, p<0.001), in ischemia recurrence (10.6% versus 31.4%,
p<0.0001), and in stroke (0.3% versus 2.5%, p<0.007) 169. As
these were small-scale studies, carried out in centers of
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excellence in interventional cardiology, and none of them
used the thrombolytic regimen considered the gold stan-
dard (accelerated t-PA), there was a considerable questio-
ning in regard to the possibility of generalizing these results
to common hospital institutions that had interventional
cardiology services. This is a crucial point because AMI has
a highly prevalent occurrence, causing 1.5 million to 2.0
million hospital admissions yearly all around the world.
Based on these premises, GUSTO IIb was designed, rando-
mizing 1,138 patients in 57 centers. In this study, the index of
normal flow obtainment (TIMI III) was 73%, quite inferior to
the indexes >90% reported in the first three studies. The
main analyzed variables showed statistically nonsignificant
reductions of mortality (5.7% versus 7.0%, p=0.37), of the
infarction recurrence index (4.5% versus 6.5%, p=0.13), and
of stroke (0.2% versus 0.9%, p=0.11). When considered
altogether, however, these variables  occured less frequently
with coronary angioplasty (9.6% versus 13.7%, p=0.03).
In the most comprehensive available metanalysis
comprising 10 randomized studies and 2,606 patients,
Weaver et al 170 observed that primary angioplasty can be
superior to thrombolysis because it offers lower mortality
rate (4.4% versus 6.5%, p=0.02), associated with a lower
recurrence of infarction (7.2% versus 11.9%, p<0.001), and a
lower incidence of cerebral hemorrhage.
However, despite the higher efficiency of primary
angioplasty evidenced in small and moderate randomized
studies and in metanalysis, two registries, NRMI-2171 and
MITI172, did not confirm these results, even though the
analysis comprised around 30 000 patients, 20% of whom
were treated with angioplasty and the remaining with throm-
bolysis. Mortality in NRMI-2 was 5.4% versus 5.2%, and in
MITI it was 5.6% versus 5.5% for angioplasty and throm-
bolysis, respectively.
Therefore, we can conclude that both recanalization
methods still present important limitations. Thrombolysis is
limited due to the following reasons: it restores normal flow
in little more than half of the patients treated; only half of the
patients are eligible for this treatment; fatal or disabling ce-
rebral hemorrhage occurs in 1% of the patients treated this
way; and there is a high index of recurrence of infarction and
ischemia with this type of treatment. On the other hand,
angioplasty is limited for the following reasons: it is not
widely available (catheterization laboratories exist in 20% of
the North American hospitals, 10% of the European hos-
pitals, and 2% of the Brazilian hospitals); when available,
there is a delay of more than two hours for the beginning of
the procedure; there is infarction recurrence in 3-5% of the
cases; there is recurrence of ischemia in 10-15% of the ca-
ses; there is angiographic restenosis in 30-50% of the cases;
the target vessel needs revascularization in six months in
20% of the cases; there is a great variability among opera-
tors and institutions.
Therefore, these limitations provide great opportuni-
ties for research with the two methods of recanalization ai-
ming to treat the highest number of patients, in the smallest
period of time, reducing immediate and mediate mortality
and morbidity. The clinical research lines concentrate in
three areas: search for the ideal thrombolytic agent and regi-
men; improvement of primary percutaneous revasculariza-
tion by the use of stents and adjunct use of platelet glyco-
protein IIbIIIa inhibitors; combination of thrombolysis and
mechanical revascularization.
The main studies involving the new thrombolytic
agents have already been mentioned. However, the newest
concept in chemical revascularization is the association of
thrombolytic agents in low doses with the potent platelet
glycoprotein IIbIIIa inhibitors. The clinical exploration of
this concept aims to make recanalization happen earlier,
increase the recanalization index, promote a sustained reca-
nalization, reduce the incidence of cerebral hemorrhage, and
enable an earlier angioplasty to treat the postthrombolysis
residual stenosis. Three pilot studies of efficiency and safe-
ty are in the final phase of analysis. The preliminary data
have been positive in showing that a low dose of t-PA and
abciximab (TIMI 14), a low dose of r-PA and abciximab
(SPEED Trial or GUSTO IV Pilot), integrilin with a low dose
of t-PA (INTRO AMI) produced recanalization indexes
equal or superior to those obtained with the conventional
dose of the thrombolytic agent, without increasing hemorr-
hagic complications. Therefore, these studies demonstrated
that platelet glycoprotein IIbIIIa inhibition facilitates throm-
bolysis. Taking this into account, a study comprising 17 000
patients will compare two thrombolysis regimens (r-PA in
conventional dose and r-PA in half of the conventional dose
associated with abciximab) having as its main goal the ana-
lysis of 30-day mortality. This study is GUSTO IV AMI and
has its recruiting phase planned for the beginning of 1999.
The improvement of primary mechanical revasculariza-
tion has involved the use of primary stent with or without
abciximab, the most exhaustively clinically tested inhibitor
of platelet glycoprotein IIbIIIa, so far. The use of primary
stent in infarction was tested in several small studies, such
as FRESCO 173, GRAMI 174, PASTA 175, Stent PAMI Pilot 176,
and the study of Suryapranata et al 177. Hospital and six-
month results have proved the superiority of the stent in
relation to angioplasty, especially for reducing the recurren-
ce of infarction, the recurrence of ischemia, and the revascu-
larization of the target vessel. The Stent PAMI Study, which
randomized around 900 patients for the two techniques of
mechanical recanalization, is in its final phase of analysis.
The other investigation line of mechanical revasculariza-
tion is its association with abciximab, and the Controlled
Abciximab and Device Investigation to Lower Late Angio-
plasty Complications (CADILLAC) Study is in its recruiting
phase of the 2,000 expected patients, who will be randomi-
zed into four groups to compare angioplasty versus stent,
with and without the use of abciximab. Another ongoing
study is the Abciximab Before Direct Angioplasty and
Stenting in Myocardial Infarction Regarding Acute and
Long-term Follow-up (ADMIRAL).
The most recent reperfusion strategy under study is
the association of thrombolysis and mechanical recanaliza-
tion. This strategy aims to maintain the advantage of easy
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and immediate administration of the thrombolytic agent in
low dose, followed by angiography to document the state
of flow and anatomical stratification. If the flow is adequate,
the dose of the thrombolytic agent is completed and the
patient is maintained under clinical treatment for six weeks,
when an evaluation with an ischemic test is performed. If the
flow is inadequate by angiography, angioplasty is perfor-
med. This study is called Plasminogen Activator Angio-
plasty Compatibility Trial (PACT), and its preliminary
results have shown significant benefits in the preservation
of the ventricular function.
Despite the unquestionable importance of the early
and long-lasting flow obtainment in the infarction-related
artery, more specific technologies to evaluate myocardial
perfusion have shown that there often is dissociation bet-
ween epicardial flow restoration and myocardial perfusion.
Among these technologies we can cite: speed of resolution
of the elevation of the ST segment 178, invasive measure-
ment of the flow speed with Doppler wire 179, positron emis-
sion tomography 180, contrast echocardiogram with micro-
bubbles 181,182. The extreme of that phenomenon is known as
no-reflow phenomenon and it uncommonly complicates
coronary angioplasty.
Conclusion
The recent advances in vascular biology and the fin-
dings of early coronary angiography and angioscopy have
allowed the establishment of the erosion or rupture of a
silent atherosclerotic plaque as the common denominator
in AISs, independent from its degree of stenosis. The
plaque complication depends on extrinsic and intrinsic
factors, and often, but not consistently, results in suboc-
clusive or temporary occlusive coronary thrombosis, which
leads to unstable angina or non-Q MI. When the coronary
thrombosis is occlusive and long-lasting, the clinical reper-
cussion is AMI. The difference between unstable angina
and AMI is the extension of the plaque rupture and subse-
quent degree of thrombosis.
Unstable angina treatment aims to control the throm-
bosis process with antithrombotic agents and to reestablish
the balance between oxygen supply and consumption with
antiischemic agents. The antithrombotic agents, either the
antiplatelet ones (acetylsalicylic acid, ticlopidine, or platelet
glycoprotein IIbIIIa inhibitors) or the antithrombotic ones
(unfractioned or low-molecular-weight heparin) are ad-
ministered to avoid the progression to long-lasting occlusi-
ve thrombosis and consequent MI or death. The antiische-
mic agents (nitrates, beta-blockers, or calcium antagonists)
are administered to abolish or treat the anginal crises.
AMI treatment aims at the immediate and stable rees-
tablishment of the flow in the infarction-related artery. The
most used therapeutical option to coronary recanalization is
the intravenous administration of thrombolytic agents
(streptokinase, TPA, or r-PA). Thrombolysis is effective in
half of the patients and its main complication is the rare
occurrence of fatal or disabling cerebral hemorrhage. In
addition, the early or late reocclusion is frequent. The alter-
native to chemical recanalization is mechanical recanaliza-
tion with primary angioplasty. Angioplasty is more effective
than thrombolysis in reestablishing a thorough and more
stable recanalization; however, it is less available and has
logistical limitations in treating a disease with such a high
prevalence as AMI.
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